Based on the analysis of clinical characteristics and chemosensitivity, it has been suggested that HER2-low breast cancer, accounting for 70% of all cases, may represent a subtype distinct from HER2-negative (IHC 0) breast cancer9–12. This evidence concerns the gene ERBB2 and breast cancer.